Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

News | December 30, 2014
December 30, 2014 — Wearable technologies, possible changes to stenting practices, state legislation on energy drinks,...
News | December 23, 2014
December 23, 2014 — The most accessed research studies in the Journal of the American College of Cardiology (JACC) in...
Alere, INRatio, INRatio2, PT/INR Monitor system, correction

Photo courtesy of Alere

News | December 16, 2014
December 16, 2014 — Alere Inc. has initiated a voluntary correction to inform United States users of the Alere INRatio...
AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab

Photo courtesy of American Stroke Association

Feature | November 24, 2014
November 16, 2014 — Long-term overtreatment with the anti-clotting drug warfarin, combined with antiplatelet therapy of...
DAPT study
Feature | November 18, 2014
November 18, 2014 — Patients who took dual antiplatelet therapy medications beyond the standard 12 months after...
News | November 12, 2014
November 12, 2014 — The actions — or inaction — of patients should be considered in programs designed to improve care...
News | September 23, 2014
September 23, 2014 — New analyses and extended follow-up from the BRIGHT study demonstrated that bivalirudin remained...
News | September 22, 2014
September 22, 2014 — According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after...
Study Blood Thinner Heart Attack Patients
Feature | September 19, 2014
September 19, 2014 — The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers...
Feature | September 19, 2014
September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-...
Professors Updated Information Aspirin Heart Attack Prevention
News | September 12, 2014
September 12, 2014 — The first researcher in the world to discover that aspirin prevents a first attack, Charles H....
U.S. Department of Justice Close Investigation PLATO Clinical Trial Ticagrelor
Feature | August 20, 2014
August 20, 2014 — AstraZeneca received confirmation from the United States Department of Justice that it is closing its...
News | July 30, 2014
July 30, 2014 — Regado Biosciences announced earlier this month it has voluntarily paused enrollment in its REGULATE-...
News | June 20, 2014
June 20, 2014 — Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in...
Technology | June 03, 2014
June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to...